financetom
Business
financetom
/
Business
/
MarketWise Drops Over 25% After CEO Resigns: Sale Of His Porter & Co. To Company 'Like Trying To Share A Ham Sandwich With A Pit Bull'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MarketWise Drops Over 25% After CEO Resigns: Sale Of His Porter & Co. To Company 'Like Trying To Share A Ham Sandwich With A Pit Bull'
Aug 12, 2024 11:50 AM

Porter Stansberry resigns as chairman and CEO of MarketWise ( MKTW ), causing a 25% drop in stock. He blames legal issues for not completing sale of his company to MarketWise ( MKTW ).MarketWise Inc. ( MKTW ) shares plummeted more than 25% since its founder Porter Stansberry announced on X on Friday evening he was resigning from the company as its chairman and CEO.

As of Monday’s mid-day trading, MarketWise ( MKTW ), a Baltimore-based investment research firm, has dropped 25.94% to 80 cents.

“It’s with sadness that I must announce my resignation from $MKTW,” he wrote on X on Friday at 7:25 p.m. ET.

“To everyone who bought shares because of my involvement in the firm, I sincerely apologize that I wasn’t able to complete my plans to turn around the company.”

In a lengthy letter that he published on X over several posts, he went on to say that he hopes MarketWise ( MKTW ), which he founded in 1999, can find new leadership after a special committee unsuccessfully tried to negotiate the sale of Porter & Co., an investment research firm that he also founded in 2022, to MarketWise ( MKTW ).

“I am resigning because after 10 months of negotiating for the sale of my company, Porter & Co., to MarketWise ( MKTW ) we have been unable to come to terms,” he wrote.

Read Also: China’s Low Consumer Confidence Creates Panic Among Global Giants: ‘We Don’t Know How Long It Will Take…’

“As you know, once the board delegated its authority to acquire Porter & Co. to a special committee of independent directors, that special committee became bound to follow the legal direction of its outside counsel, lest the members of the special committee subject themselves to personal liability by closing the deal without counsel's endorsement.

“As result, I never had the opportunity to negotiate fairly with my partners. Instead, I was left trying to negotiate a ‘friendly transaction’ with what appear to be some of the fiercest litigators in the U.S. It was like trying to share a ham sandwich with a pit bull.”

Stansberry said he finds it “a mystery” that the committee could not work with its counsel to close the deal on agreeable terms in a timely manner, since an overwhelming majority of shareholders supported it and it is in the company’s best interests.

“After all, the opportunity to purchase for only $10 million up front (25% of the purchase price), a business with more than 25,000 customers that produced $28 million in billings in 2023, that boasted a $1,999 ARPU that year, and that is on track this year to grow its subscriber base by 30% — shouldn't have been a hard sell,” he wrote.

“In short, I was going to give you a great business, that would pay for itself. All you had to do was say yes.”

But the committee and the counsel were unable — or unwilling — to close the deal after signing a letter of intent on Nov. 3, he said.

“After spending more than half a million dollars on this deal (and after working for you for free for 10 months) I simply cannot continue this process. Regrettably, I must, and hereby do, resign as chairman and CEO of MarketWise.”

Read Now:

Oil Prices Eye Fourth Straight Day Of Gains As Geopolitical Risks Overshadow OPEC’s Cooler Demand Forecast

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arrowhead Pharmaceuticals Requests Regulatory Clearance for Tauopathies Phase 1/2a Study
Arrowhead Pharmaceuticals Requests Regulatory Clearance for Tauopathies Phase 1/2a Study
Sep 10, 2025
08:00 AM EDT, 09/10/2025 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Wednesday it filed a request for regulatory clearance to launch a phase 1/2a clinical trial of ARO-MAPT for the potential treatment of tauopathies, including Alzheimer's disease. The application was submitted to the New Zealand Medicines and Medical Devices Safety Authority for review by the standing committee on...
Joby to bring helicopter and seaplane rides to Uber app as soon as 2026
Joby to bring helicopter and seaplane rides to Uber app as soon as 2026
Sep 10, 2025
Sept 10 (Reuters) - Air-taxi maker Joby Aviation ( JOBY ) said on Wednesday that it planned to bring Blade's helicopter and seaplane services to the Uber ( UBER ) app as soon as next year. Joby acquired Blade Air Mobility's passenger business in August for up to $125 million, and plans to use the helicopter ride-share firm's infrastructure to...
BRIEF-GE Healthcare to Acquire Icometrix, Expanding AI-Powered Brain MRI Capabilities
BRIEF-GE Healthcare to Acquire Icometrix, Expanding AI-Powered Brain MRI Capabilities
Sep 10, 2025
Sept 10 (Reuters) - GE Healthcare Technologies Inc ( GEHC ) : * GE HEALTHCARE ANNOUNCES INTENT TO ACQUIRE ICOMETRIX TO STRENGTHEN NEUROLOGY PORTFOLIO WITH BRAIN MRI ASSESSMENT SOLUTIONS * GE HEALTHCARE ( GEHC ): GE HEALTHCARE INTENDS TO FUND THIS TRANSACTION WITH CASH ON HAND * GE HEALTHCARE ( GEHC ): FINANCIAL DETAILS OF TRANSACTION HAVE NOT BEEN DISCLOSED...
Lyft, May Mobility roll out robotaxi service in Atlanta
Lyft, May Mobility roll out robotaxi service in Atlanta
Sep 10, 2025
* Robotaxis can be hailed in the Lyft ( LYFT ) app * Toyota Sienna minivans retrofitted by May Mobility * May Mobility manages fleet, not Lyft's ( LYFT ) Flexdrive unit By Akash Sriram Sept 10 (Reuters) - Ride-hailing app Lyft ( LYFT ) and autonomous vehicle startup May Mobility will launch a pilot robotaxi service in Atlanta starting...
Copyright 2023-2026 - www.financetom.com All Rights Reserved